Joseph Khoury
Overview
Explore the profile of Joseph Khoury including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
1852
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Solorzano J, Menendez V, Parra E, Solis L, Salazar R, Garcia-Cosio M, et al.
Oncoimmunology
. 2024 Aug;
13(1):2388304.
PMID: 39135889
The Hodgkin and Reed - Sternberg (HRS) cells in classical Hodgkin Lymphoma (cHL) actively modify the immune tumor microenvironment (TME) attracting immunosuppressive cells and expressing inhibitory molecules. A high frequency...
2.
Zhao Y, Short N, Kantarjian H, Chang T, Ghate P, Qu C, et al.
Blood
. 2024 Mar;
144(1):61-73.
PMID: 38551807
Inotuzumab ozogamicin (InO) is an antibody-drug conjugate that delivers calicheamicin to CD22-expressing cells. In a retrospective cohort of InO-treated patients with B-cell acute lymphoblastic leukemia, we sought to understand the...
3.
Baskovich B, Baras A, Seethala R, Fitzgibbons P, Schneider F, Harris B, et al.
Arch Pathol Lab Med
. 2024 Feb;
148(10):1105-1109.
PMID: 38375737
Context.—: Biomarker reporting has increasingly become a key component of pathology reporting, providing diagnostic, prognostic, and actionable therapeutic data for patient care. Objective.—: To expand and improve the College of...
4.
Zhao Y, Short N, Kantarjian H, Chang T, Ghate P, Qu C, et al.
medRxiv
. 2023 Dec;
PMID: 38106221
Key Points: We identified multiple mechanisms of CD22 antigen escape from inotuzumab ozogamicin, including protein truncation, protein destabilization, and epitope alteration.Hypermutation caused by error-prone DNA damage repair was a driver...
5.
Alaggio R, Amador C, Anagnostopoulos I, Attygalle A, de Oliveira Araujo I, Berti E, et al.
Leukemia
. 2023 Jul;
37(9):1944-1951.
PMID: 37468552
No abstract available.
6.
Senapati J, Muftuoglu M, Ishizawa J, Abbas H, Loghavi S, Borthakur G, et al.
Blood Cancer J
. 2023 Jun;
13(1):101.
PMID: 37386016
In TP53 wild-type acute myeloid leukemia (AML), inhibition of MDM2 can enhance p53 protein expression and potentiate leukemic cell apoptosis. MDM2 inhibitor (MDM2i) monotherapy in AML has shown modest responses...
7.
Hunker J, Tarpada S, Khoury J, Goch A, Kahn M
Cureus
. 2023 May;
15(4):e37502.
PMID: 37187642
Background: Brazilian jiu-jitsu (BJJ) is a martial art that focuses on ground combat, emphasizing skill over strength and submission over striking. The purpose of this study is to evaluate the...
8.
Jabbour E, Short N, Senapati J, Jain N, Huang X, Daver N, et al.
Lancet Haematol
. 2023 May;
10(6):e433-e444.
PMID: 37187201
Background: The outcome of older patients with B-cell acute lymphocytic leukaemia is inferior to that in younger patients due to the adverse disease biology and their inability to tolerate intensive...
9.
Jelloul F, Quesada A, Yang R, Li S, Wang W, Xu J, et al.
Mod Pathol
. 2023 Mar;
36(6):100166.
PMID: 36990279
The development of therapy-related myeloid neoplasms (t-MN) is a rare complication that can occur in myeloma patients treated primarily with novel therapies. To better understand t-MNs in this context, we...
10.
Pemmaraju N, Kantarjian H, Sweet K, Wang E, Senapati J, Wilson N, et al.
Blood
. 2022 Nov;
141(6):567-578.
PMID: 36399715
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with historically poor outcomes and no worldwide consensus treatment approach. Unique among most hematologic malignancies for its frequent cutaneous...